Celgene aims to block a generic of blood cancer treatment Revlimid

08/25/2010 | Wall Street Journal, The

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care